About Intabio
Intabio is a company based in Sunnyvale (United States) founded in 2015 by Lena Wu and Erik Gentalen was acquired by SCIEX in January 2021. Intabio has raised $30.7 million across 4 funding rounds from investors including SCIEX, Genoa Ventures and Vertical Venture Partners. Intabio operates in a competitive market with competitors including Biological Dynamics, Epicore Biosystems, Miroculus, Achira and NanoTemper, among others.
- Headquarter Sunnyvale, United States
- Founders Lena Wu, Erik Gentalen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Intabio
Unlock access to complete
Software Development Team
49 people
Sales and Marketing
47 people
Senior Team
29 people
Leadership Team
25 people
Human Resources and Administration
22 people
Finance and Accounting
19 people
Product Management Team
15 people
Sr. Team
9 people
Unlock access to complete
Funding Insights of Intabio
Intabio has successfully raised a total of $30.7M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $18 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intabio
Intabio has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include SCIEX, Genoa Ventures and Vertical Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage VC firm focused on life science startups
|
Locked | Locked | Locked | |
|
Early-stage venture capital investments are made in specific industry verticals.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked |
Investor details for Intabio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intabio
Investment portfolio details for Intabio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Intabio
Detailed financials for Intabio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intabio Comparisons
Peer comparison for Intabio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intabio
Intabio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological Dynamics, Epicore Biosystems, Miroculus, Achira and NanoTemper, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Proprietary lab-on-chip platform for nanoparticle isolation is offered.
|
|
| Locked | Locked | Locked |
Wearable sweat-based microfluidic sensing systems are provided for health monitoring.
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
|
| Locked | Locked | Locked |
Provider of diagnostic medical devices for screening Covid 19
|
|
| Locked | Locked | Locked |
Develops tools for protein characterization & analysis
|
|
| Locked | Locked | Locked |
Microfluidics, biochips, and high-throughput gene-editing technologies are manufactured.
|
Detailed competitors of Intabio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intabio
Complete news archive for Intabio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intabio
Intabio was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Intabio is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Lena Wu is the current CEO of Intabio. They have also founded this company.
Intabio is a funded company, having raised a total of $30.7M across 4 funding rounds to date.
Intabio provides an analytical platform to accelerate the development of biotherapeutic drugs. It is developing an instrumentation system called Blaze comprised of a bench-top instrument, microfluidic chip, and reagent kit. The system uses a proprietary microfluidic platform and provides separation of intact protein isoforms by charge heterogeneity analysis (cIEF), imaging at 280nm for quantitation of each protein isoform, and sample preparation and electrospray delivery into an adjacent mass spectrometer in order to identify the unknown modifications. Claims that by enabling the interrogation of product quality earlier in the development process, the system provides insights for key development decisions and can reduce the risk of downstream bioproduction issues.
Intabio's top competitors include Epicore Biosystems, Biological Dynamics and Achira.
Intabio has 7 investors. Key investors include SCIEX, Genoa Ventures, Vertical Venture Partners, Northpond Ventures, and National Science Foundation.